Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5000-5005

  Mita, Alain C ^a   Mita, Monica M ^a   Nawrocki, Steffan T ^a   Giles, Francis J ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CASPASE 9; CISPLATIN; EM 1241; EM 1421; ETOPOSIDE; ISIS 23722; LY 2181308; PACLITAXEL; PROTEIN P53; SURVIVIN; TUBULIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTHRALGIA; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME SEGREGATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOKINESIS; CYTOSOL; DIARRHEA; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; GAMMA IRRADIATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; KIDNEY TUBULE NECROSIS; MELANOMA; METHYLATION; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; WILD TYPE; ANIMAL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 52649172153     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0746     Document Type: Review

References (85)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Cryns V. Yuan J. Proteases to die for. Genes Dev 1998;12:1551-70.
3. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90.
4. Hanahan D WR. The hallmarks of cancer. Cell 2000;100:57-70.
5. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001;26:61-6.
6. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
7. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
8. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
9. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-52.
10. Sanna MG, da Silva Correia J, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002;22:1754-66.
11. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10.
12. Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol 1999;19:388-98.
13. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
14. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
15. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
16. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual α-helical extensions. Mol Cell 2000;6:183-9.
17. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A 1999;96:1457-62.
18. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344 Pt 2:305-11.
19. Van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by NF-kB. Trends Cell Biol 1998;8:107-11.
20. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007;26:2678-84.
21. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003;22:4266-80.
22. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004;23:6170-4.
23. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
24. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
25. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
26. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002;303:124-31.
27. Noton EA, Colnaghi R, Tate S, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006;281:1286-95.
28. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003;100:13791-6.
29. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000;113 Pt 23:4363-71.
30. Altieri DC. Coupling apoptosis resistance to the cellular stress response: the IAP-Hsp90 connection in cancer. Cell Cycle 2004;3:255-6.
31. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54.
32. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-7.
33. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006;18:609-15.
34. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT. Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cel 2002;13:3064-77.
35. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001;11:886-90.
36. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 2004;118:187-202.
37. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004;166:179-91.
38. Lens SM, Vader G, Medema RH.The case for survivin as mitotic regulator. Curr Opin Cell Biol 2006;18:616-22.
39. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117-27.
40. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (lAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59.
41. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003;22:2729-40.
42. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087-90.
43. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-3.
44. Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664-7.
45. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001;98:2091-100.
46. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001;32:119-25.
47. Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
48. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
49. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001;23:251-8.
50. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
51. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-8.
52. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11:186-93.
53. Islam A, Kageyama H,Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23.
54. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81.
55. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001;169:155-64.
56. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999;59:3143-51.
57. Engels K, Knauer SK, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007;211:532-40.
58. Saito T, Arifin MT, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 2007;82:193-8.
59. Marioni G, Bertolin A, Giacomelli L, et al. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res 2006;26:3813-7.
60. Osaka E, Suzuki T, Osaka S, et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 2006;39:95-100.
61. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106-13.
62. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
63. Kenney DM, Geschwindt RD, Kary MR, Linic JM, Sardesai NY, Li ZQ. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 2007;28:57-62.
64. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13:4407-14.
65. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007;96:639-45.
66. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81:824-31.
67. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, et al. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 2005;55:324-30.
68. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-8.
69. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-5.
70. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998;273:11177-82.
71. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999;264:781-8.
72. Harfouche R, Hassessian HM, Guo Y, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002;64:135-47.
73. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757-65.
74. Reed JC. The survivin saga goes in vivo. J Clin Invest 2001;108:965-9.
75. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002;5:65-72.
76. Andersen MH, Thor SP. Survivin-a universal tumor antigen. Histol Histopathol 2002;17:669-75.
77. Ling X, Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 2004;36:450-4, 6-60.
78. Mita A, Antonia S, Lewis L, et al. Final safety, pharmacokinetic and antitumor activity results of a phase I study of YM155, a novel survivin inhibitor, when administered by 168 hour continuous infusion. 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," Prague 2006.
79. Nakagawa K, Satoh T, Okamoto I, et al. Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007;25:147S.
80. KaravasilisV, Mita A, Hudes G, et al. Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007;25:268S.
81. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kB targets BCL2 and BIRC5/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005;206:123-34.
82. Sato A, Ito K, Asano T, Sumitomo M, AsanoT, Hayakawa M. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int J Oncol 2007;30:695-700.
83. Li B, Fan J, Liu X, et al. Suppression of colorectal tumor growth by regulated survivin targeting. J Mol Med 2006;84:1077-86.
84. Wagner M, Schmelz K, Db̈rken B,Tamm I. Transcriptional regulation of survivin gene expression in colon adenocarcinoma. AACR Annual Meeting 2007.
85. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007;67:339-45.